The Estée Lauder Companies is committing $15 million over five years to establish a new international research initiative focused on breast cancer among younger women. Created in partnership with the Breast Cancer Research Foundation (BCRF), the Global Research Initiative on Breast Cancer in Younger Women will bring scientists from different countries and institutions together to investigate why diagnoses are increasing in women under 45.
Key takeaways: Estée Lauder
- The program builds on more than 30 years of collaboration between Estée Lauder and BCRF and addresses what the companies describe as a significant gap in research funding for early-onset breast cancer.
- Women diagnosed before the age of 40 are nearly 40% more likely to die from the disease, according to the figures cited by the initiative.
- By bringing researchers together across countries and disciplines, BCRF and Estée Lauder aim to create greater opportunities for researchers to share findings and build on each other's work.
The program builds on more than 30 years of collaboration between Estée Lauder and BCRF and addresses what the companies describe as a significant gap in research funding for early-onset breast cancer. Diagnoses among women younger than 45 increased by 11% between 2012 and 2022, while only an estimated 0.6% of breast cancer research funding since 2020 has focused specifically on younger women.
The funding gap also has implications for breast cancer diagnostics, particularly as younger patients can face different disease characteristics and diagnostic challenges than older populations. Breast cancer diagnosed in younger women is more likely to be identified at a later stage and can behave more aggressively. Women diagnosed before the age of 40 are nearly 40% more likely to die from the disease, according to the figures cited by the initiative.
The new research coalition will initially focus on understanding the biological mechanisms associated with early-onset breast cancer. Scientists will investigate factors that may contribute to the development and progression of the disease, with the broader objective of generating evidence that can support improved risk prediction, prevention, early detection and treatment.
The initiative is designed as a coordinated international research effort rather than a single institutional program. By bringing researchers together across countries and disciplines, BCRF and Estée Lauder aim to create greater opportunities for researchers to share findings and build on each other’s work.
Global Research Program Targets Early-Onset Breast Cancer
The first grant from the initiative will support the initial research phase, with a specific emphasis on the biology of breast cancer in younger women. Researchers will examine the mechanisms behind early-onset disease to establish a stronger scientific basis for future studies.
Understanding these mechanisms could have implications across the breast cancer care pathway. Greater knowledge of how breast cancer develops in younger patients could contribute to research into who may face higher risk, how the disease can be detected earlier and which approaches may be appropriate for different patient groups.
The research also has potential relevance to breast cancer diagnostics. Earlier identification is particularly important when disease is diagnosed at a younger age and may have more aggressive characteristics. However, the initiative is focused on generating scientific evidence rather than introducing a specific diagnostic technology or screening product.
The program’s global structure is another central feature. Scientists from multiple countries, institutions and research disciplines will collaborate through a common research effort. The organizations involved expect this model to help reduce duplication, improve knowledge sharing and accelerate the movement of findings from laboratory research toward patient care.
Insights generated during the first phase will also be used to determine subsequent research priorities. This creates a staged approach in which initial findings about the biology of early-onset breast cancer can guide later investigations into prevention, detection and treatment.
For the broader research community, the initiative arrives at a time when younger-age breast cancer has received increasing attention because of rising diagnosis rates. The funding commitment is intended to address an area that has historically received a relatively small portion of overall breast cancer research investment.
William P. Lauder, Chair of the Board of Directors of The Estée Lauder Companies and Co-Chair of BCRF, said the company’s commitment reflects the vision of his mother, Evelyn H. Lauder, who helped establish the company’s long-running focus on breast cancer research. He said the new funding would support efforts to better understand the disease in younger women.
Estée Lauder and BCRF Expand Longstanding Research Partnership
The new initiative extends a relationship between The Estée Lauder Companies and BCRF that has lasted for more than three decades. The partnership has historically supported breast cancer research, and the latest commitment shifts a significant portion of that attention toward the specific challenges associated with early-onset disease.
Stéphane de La Faverie, President and CEO of The Estée Lauder Companies and President of The Estée Lauder Companies Charitable Foundation, said the rise in diagnoses among younger women creates an urgent need for additional research and international collaboration.
The $15 million commitment will come from The Estée Lauder Companies Charitable Foundation. The funding is intended to support the coordinated research program and its initial scientific work rather than a commercial healthcare product.
Donna McKay, President and CEO of BCRF, said the organization has already supported research involving younger women and described the new program as an opportunity to coordinate researchers on a larger international scale. She said the increase in incidence among younger women warrants greater investment in research aimed at understanding the disease.
The initiative could also help create a more connected research environment around early-onset breast cancer. Researchers working in different countries or specialties can often approach the disease from different scientific perspectives. Bringing those efforts into a coordinated program could help connect findings across biological research, detection and treatment studies.
For Estée Lauder, the announcement reinforces its long-standing involvement in breast cancer research while directing new funding toward a specific area of unmet research need. For BCRF, the initiative provides funding for a larger collaborative effort focused on understanding why breast cancer is increasingly affecting younger women.
The immediate research focus will remain on disease biology. Over time, the findings are expected to inform further investigations into risk prediction, prevention, early detection and treatment. The organizations involved will therefore need to translate laboratory discoveries into clinically useful knowledge before the program’s broader impact can be assessed.
With a five-year commitment and an international research structure, the initiative establishes a dedicated platform for studying early-onset breast cancer. Its progress will ultimately depend on the discoveries generated by participating scientists and how effectively those findings can move into clinical research and patient care.x
Ref: https://www.afp.com/de/node/3843163
Explore more Press Releases coverage from MedGadget.
